A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEXAfter Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Anti-TA-MUC1 monoclonal antibody (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Glycotope
- 15 Aug 2017 This study has been discontinued in Hungary as per Eudra.
- 13 Aug 2017 This study has been discontinued in Germany as per Eudra.
- 13 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.